Editors: Atta-ur-Rahman, FRS , M. Iqbal Choudhary

Anti-Angiogenesis Drug Discovery and Development

Volume 3

eBook: US $149 Special Offer (PDF + Printed Copy): US $253
Printed Copy: US $179
Library License: US $596
ISSN: 2452-3240 (Print)
ISSN: 2210-268X (Online)
ISBN: 978-1-68108-156-4 (Print)
ISBN: 978-1-68108-155-7 (Online)
Year of Publication: 2016
DOI: 10.2174/97816810815571160301

Introduction

The inhibition of angiogenesis is an effective mechanism of slowing down tumor growth and malignancies. The process of induction or pro-angiogenesis is highly desirable for the treatment of cardiovascular diseases, wound healing disorders, etc. Efforts to understand the molecular basis, both for inhibition and induction, have yielded fascinating results.

Anti-angiogenesis Drug Discovery and Development provides an excellent compilation of well-written reviews on various aspects of the anti-angiogenesis process. These reviews have been contributed by leading practitioners in drug discovery science and highlight the major developments in this exciting field in the last two decades. The feast of these reader-friendly reviews on topics of great scientific importance – many of which are considered significant medical breakthroughs, makes this book excellent reading both for the novice as well as for expert medicinal chemists and clinicians.

This volume brings together 5 reviews on these topics:

-Beta-blockers for treating premature retinopathy

-Anti-angiogenic activity of disintegrin-based, synthetic cyclic KTS peptides

-Anti-angiogenic therapy of lung cancer

-Oral anti-angiogenic therapy for NSCLC

-Angiogenesis in hepatocellular carcinoma

Indexed in: EBSCO, Ulrich's Periodicals Directory.

Preface

- Pp. i-iii (3)
Atta-ur-Rahman, M. Iqbal Choudhary
Download Free

List of Contributors

- Pp. iv-v (2)
Atta-ur-Rahman, M. Iqbal Choudhary
Download Free

Beta-Blocker Therapy for Retinopathy of Prematurity

- Pp. 3-15 (13)
Imad R. Makhoul, Tatiana Smolkin, David Warburton
View Abstract

Disintegrin-Based, Synthetic Cyclic KTS Peptides as Novel Dual Antagonists of α1β1/α2β1 Integrins with Antiangiogenic Activity

- Pp. 16-45 (30)
Tatjana Momic, Jehoshua Katzehendler, Efrat Noy, Hanoch Senderowitz, Johannes A. Eble, Cezary Marcinkiewicz, Philip Lazarovici
View Abstract

Current Status of Anti-Angiogenic Therapy in the Clinical Management of Lung Cancer

- Pp. 49-69 (21)
Peter M. Ellis, Abdulaziz Al Farsi
View Abstract

Angiogenesis in Hepatocellular Carcinoma (HCC) and its Potential Applications in the Development of Anti-HCC Drugs

- Pp. 97-174 (78)
Guang-Chun Sun, Dai-Wei Zhao, Xu Yang, Lichun Sun
View Abstract

Bevacizumab for Glioblastoma Treatment: Reviewing Biological and Clinical Hypothesis for its Success and Failures

- Pp. 175-226 (52)
Ana C. Fernandes, Cláudia Caeiro, Vera Miranda-Gonçalves, Fernanda Cury, Margarida Damasceno, Rui M. Reis, Olga Martinho
View Abstract

Subject Index

- Pp. 227-240 (14)
Atta-ur-Rahman, M. Iqbal Choudhary
Download Free